Bone Therapeutics signed an exclusive agreement with Link Health and Shenzhen Pregene Biopharma to support manufacture, clinical development and commercialization of ALLOB allogeneic, off-the-shelf, bone cell therapy in China, Taiwan, Singapore, South Korea and Thailand.
Bone Therapeutics can receive up to €55 million (~USD $65 million) in development, regulatory and commercial milestone payments, including €10 million in upfront and milestone payments, anticipated in the next 24 months. The company is also entitled to tiered double-digit royalties on annual net sales of ALLOB.
Bone Therapeutics retains development and commercialization rights to ALLOB in all other geographies outside of those covered by this agreement, and will continue to develop and commercialize plans for ALLOB in the U.S. and Europe.
“This collaboration between Bone Therapeutics, Link Health and Pregene expands our geographic reach and demonstrates the global commercial potential of ALLOB,” said Miguel Forte, M.D., Ph.D., Chief Executive Officer of Bone Therapeutics. “We already have operational experience in Asia with the Phase III clinical trial of our lead product JTA-004 in Hong Kong. We selected Link Health and Pregene to partner with us in Asia as a result of their expertise in advanced therapeutics and cell therapies, their proven track record of development and commercial implementation in Chinese and Asian markets, and Pregene’s well established cell therapy manufacturing capacity.”
In preclinical studies, ALLOB has been shown to reduce healing time in a delayed-union fracture model by half, and has demonstrated good tolerability and signs of efficacy in two Phase IIa studies for two separate indications.
Bone Therapeutics signed an exclusive agreement with Link Health and Shenzhen Pregene Biopharma to support manufacture, clinical development and commercialization of ALLOB allogeneic, off-the-shelf, bone cell therapy in China, Taiwan, Singapore, South Korea and Thailand.
Bone Therapeutics can receive up to €55 million (~USD $65 million)...
Bone Therapeutics signed an exclusive agreement with Link Health and Shenzhen Pregene Biopharma to support manufacture, clinical development and commercialization of ALLOB allogeneic, off-the-shelf, bone cell therapy in China, Taiwan, Singapore, South Korea and Thailand.
Bone Therapeutics can receive up to €55 million (~USD $65 million) in development, regulatory and commercial milestone payments, including €10 million in upfront and milestone payments, anticipated in the next 24 months. The company is also entitled to tiered double-digit royalties on annual net sales of ALLOB.
Bone Therapeutics retains development and commercialization rights to ALLOB in all other geographies outside of those covered by this agreement, and will continue to develop and commercialize plans for ALLOB in the U.S. and Europe.
“This collaboration between Bone Therapeutics, Link Health and Pregene expands our geographic reach and demonstrates the global commercial potential of ALLOB,” said Miguel Forte, M.D., Ph.D., Chief Executive Officer of Bone Therapeutics. “We already have operational experience in Asia with the Phase III clinical trial of our lead product JTA-004 in Hong Kong. We selected Link Health and Pregene to partner with us in Asia as a result of their expertise in advanced therapeutics and cell therapies, their proven track record of development and commercial implementation in Chinese and Asian markets, and Pregene’s well established cell therapy manufacturing capacity.”
In preclinical studies, ALLOB has been shown to reduce healing time in a delayed-union fracture model by half, and has demonstrated good tolerability and signs of efficacy in two Phase IIa studies for two separate indications.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
